A new approach to gene editing, known as base editing, has demonstrated initial success in lowering cholesterol levels in individuals with familial hypercholesterolemia, a common genetic condition. The findings, published online March 3, 2026, in Nature Medicine, represent a significant step forward in the development of potentially long-lasting treatments for this condition, though researchers caution that further optimization and rigorous testing are needed.
Familial hypercholesterolemia affects an estimated 1 in 250 people worldwide, leading to dangerously high levels of LDL cholesterol – often referred to as “disappointing” cholesterol – and a significantly increased risk of early-onset heart disease. Current treatments, such as statins, can facilitate manage cholesterol, but they require lifelong adherence and don’t address the underlying genetic cause. This new research targets the root of the problem by aiming to permanently alter the faulty gene responsible for elevated cholesterol.
The phase 1 clinical trial focused on a single-course CRISPR base-editing therapy targeting the PCSK9 gene. PCSK9 provides instructions for making a protein that helps control the amount of cholesterol in the blood. By editing this gene, the therapy aims to reduce the production of the PCSK9 protein, thereby lowering LDL cholesterol levels. The trial involved a small number of participants, and the primary goal was to assess the safety and feasibility of the approach, rather than definitively proving its effectiveness. Yet, initial results indicate the therapy was well-tolerated and showed evidence of editing the PCSK9 gene in the liver.
How Base Editing Differs from Traditional CRISPR
While both base editing and traditional CRISPR-Cas9 gene editing involve making changes to DNA, they differ in their approach. Traditional CRISPR acts like molecular scissors, cutting both strands of the DNA double helix. This can sometimes lead to unintended consequences, such as insertions or deletions of genetic material. Base editing, allows for precise changes to individual DNA bases – the building blocks of DNA – without cutting the DNA strand. This potentially reduces the risk of off-target effects and makes it a more refined gene-editing tool. David Liu, a pioneer in base editing and prime editing, was awarded the 2025 Breakthrough Prize for his work in this field, according to the-scientist.com.
Early Trial Results and Future Directions
Sekar Kathiresan, CEO of Verve Therapeutics, the company developing the therapy, described the initial dosing of a patient as a “watershed moment” in the field of gene editing for cardiovascular disease, as reported by CRISPR Medicine. The phase 1 trial is designed to evaluate the safety and optimal dosage of the base-editing therapy. Researchers are as well working to improve the efficiency of the editing process and minimize any potential off-target effects. Preclinical studies in nonhuman primates and mouse models have shown promising efficacy and safety, as detailed in research published in Circulation.
Turning this promising early data into a transformative therapy will require careful attention to several key areas. These include optimizing editing efficiency to ensure a sufficient number of cells are successfully edited, rigorously assessing long-term safety, identifying the patients most likely to benefit from the treatment, and designing clinical trials that can definitively demonstrate its effectiveness. Further research is also needed to understand the durability of the editing effect – how long the lowered cholesterol levels will persist after a single treatment.
The development of base editing therapies for familial hypercholesterolemia represents a significant milestone in the field of genetic medicine. While challenges remain, the initial results offer hope for a future where a single treatment could provide a lasting solution for individuals at risk of early heart disease due to this common genetic condition.
What are your thoughts on the potential of gene editing for treating inherited diseases? Share your comments below.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
